Mexico’s regulatory authority, COFEPRIS, has issued new measures to simplify medical device registration, including clearer application codes by risk class and reduced approval timelines. These updates aim to streamline market access for both domestic and international manufacturers while maintaining regulatory oversight.
Following our previous updates on “COFEPRIS Streamlines Medical Device Registration: Key Takeaways from Articles 22 to 25 of the Official Gazette” (July 7) and “Mexico COFEPRIS 2025 Abbreviated Pathway for Medical Devices” (August 6), Mexico’s regulatory authority, COFEPRIS, has issued a new update on August 22, 2025. This update aims to further simplify medical device registration in Mexico.
The new agreement consolidates procedures, introduces new homoclaves for low- and higher-risk devices, and cites legal provisions to reduce bureaucratic steps. These measures are designed to help both domestic and foreign manufacturers achieve faster, more efficient regulatory approvals.
1. Elimination of Redundant Documentation
Manufacturers will no longer need to resubmit documents already issued by COFEPRIS, such as permits or certificates. This change reduces unnecessary paperwork and prevents delays caused by duplicate submissions.
2. Introduction of new Homoclaves
Clear homoclaves have been established for different categories of medical devices, distinguishing between low-risk and higher-risk products. This classification enables manufacturers to quickly determine the regulatory requirements for their devices, simplifying the application process.
3. Merging and Debugging of Application Modes and Codes
The agreement addresses the complexity of multiple overlapping application types by merging and clarifying modes and codes. This makes it easier for manufacturers to identify the correct pathway for their devices, whether low-risk consumables or high-risk implantables.
4. Time Reduction for Approvals
Approval timelines have been shortened. Certain sanitary registrations that previously required 30 business days are now set at 20 business days. While practical outcomes depend on implementation, this change signals COFEPRIS’s intent to accelerate the review process, benefiting companies introducing urgent or innovative devices.
In addition to these medical device–specific measures, the agreement introduces broader regulatory improvements:
For manufacturers—both domestic and foreign—these reforms bring tangible benefits:
For patients and healthcare providers, these changes mean earlier access to innovative medical devices, from diagnostic tools to life-saving implants, without compromising safety or quality.
The August 22, 2025 COFEPRIS simplification agreement, effective October 6, 2025, represents a milestone for Mexico’s medical device sector. By eliminating redundant requirements, merging application pathways, and shortening approval timelines, COFEPRIS is creating a more agile and predictable regulatory environment.
If effectively implemented, these reforms could make Mexico a more attractive market for medical device innovation while ensuring that patients benefit from faster access to advanced healthcare technologies.
Internal links:
External links:
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us